Supplementary Figure 2.jpg (89.18 kB)

Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients - Supplementary Figure 2

figure

posted on 2022-01-06, 10:53 authored by Jianbo Zhu, Guangpeng Chen, Kai Niu, Yongdong Feng, Lijiao Xie, Si Qin, Zhongyu Wang, Jixi Li, Song Lang, Wenlei Zhuo, Zhengtang Chen, Jianguo Sun

Supplementary Figure 2. Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients

Grading of Radiation pulmonary fibrosis after radiotherapy

Funding

This study was supported by the National Key Research & Development Program (No. 2016YFC0106400), the National Natural Science Foundation of China (81773245, 81972858), the Technology Innovation and Application Development Project of Chongqing (cstccxljrc201910), and the Cultivation Program for Clinical Research Talents of Army Medical University (2018XLC1010).

History

Usage metrics

Read the peer-reviewed publication

Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients

Future Oncology

Keywords

Recombinant human endostatin (Rh-endostatin)Non-small cell lung cancer (NSCLC)Radiotherapy Peri-radiotherapy period Radiation Therapy Solid Tumours Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

Licence

CC BY-NC-ND 4.0